GlassScriptPhysician profile
Camilla L Davis
NPI 1407159288
$4,043.40
in general payments reported to CMS, 2019-2025
42 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,043 · 2022: $541 · 2023: $690 · 2024: $619 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,459.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,496.18 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.35 | 2021-2023 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Amgen INC. | $300.74 | 2021-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $244.14 | 2021-2025 | Nucala, Trelegy Ellipta |
| Novo Nordisk INC | $221.33 | 2021-2024 | Ozempic, Rybelsus |
| Kowa Pharmaceuticals America, INC. | $130.81 | 2021 | |
| Neurocrine Biosciences, INC. | $122.88 | 2023-2024 | Ingrezza |
| Daiichi Sankyo INC. | $95.67 | 2021-2022 | |
| Abbvie INC. | $94.33 | 2021-2023 | |
| Mylan Specialty L.P. | $76.62 | 2021-2024 | Yupelri |
| Pfizer INC. | $69.18 | 2022-2024 | |
| Currax Pharmaceuticals LLC | $62.36 | 2024 | Contrave |
| Bayer Healthcare Pharmaceuticals INC. | $48.41 | 2021-2022 | |
| Abbott Laboratories | $48.12 | 2023 | Freestyle Libre 3 |
| Astellas Pharma US INC | $45.58 | 2023-2024 | Veozah |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Camilla Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.